Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability
Sign Up to like & getrecommendations! Published in 2025 at "Advances in Therapy"
DOI: 10.1007/s12325-025-03240-5
Abstract: This study was conducted to fulfill the FDA requirement for the designation of adalimumab-fkjp, an FDA-approved biosimilar, as an ‘interchangeable’ biosimilar to the reference adalimumab. The primary objective was to evaluate the interchangeability of adalimumab-fkjp… read more here.
Keywords: interchangeability; adalimumab fkjp; psoriasis; reference adalimumab ... See more keywords
Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Dermatology"
DOI: 10.1111/ijd.16399
Abstract: hypertrichosis in this child. The treatment was stopped, and the patient was switched back to tacrolimus. No treatment was performed on our pediatric patients because safe treatment was a priority over cosmetic needs. Acquired local… read more here.
Keywords: biosimilar assessment; reference adalimumab; hypertrichosis; alopecia areata ... See more keywords